Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)

被引：49

作者：

Costello, Caitlin L. ^{[1
]}

Gregory, Tara K. ^{[2
]}

Ali, Syed Abbas ^{[3
]}

Berdeja, Jesus G. ^{[4
]}

Patel, Krina K. ^{[5
]}

Shah, Nina D. ^{[6
]}

Ostertag, Eric ^{[7
]}

Martin, Chris ^{[7
]}

Ghoddusi, Majid ^{[7
]}

Shedlock, Devon J. ^{[7
]}

Spear, Matthew A. ^{[7
]}

Orlowski, Robert Z. ^{[8
]}

Cohen, Adam D. ^{[9
]}

机构：

[1] Univ Calif San Diego, Dept Med, Moores Canc Ctr, Div Blood & Marrow Transplantat, La Jolla, CA 92093 USA

[2] Sarah Cannon Res Inst, Nashville, TN USA

[3] Johns Hopkins Univ Hosp, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21287 USA

[4] Sarah Cannon Ctr Blood Canc, Nashville, TN USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[6] Univ Calif San Francisco, San Francisco, CA 94143 USA

[7] Poseida Therapeut Inc, San Diego, CA USA

[8] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA

[9] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

来源：

关键词：

D O I：

10.1182/blood-2019-129562

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3184

引用

页数：3